Abstract:Botulinum neurotoxins (BoNTs) are a family of bacterial toxins with seven major serotypes (BoNT/A-G). The ability of these toxins to target and bind to motor nerve terminals is a key factor determining their potency and efficacy. Among these toxins, BoNT/B is one of the two types approved for medical and cosmetic uses. Besides binding to well-established receptors, an extended loop in the C-terminal receptor-binding domain (HC) of BoNT/B (HC/B) has been proposed to also contribute to toxin binding to neurons by interacting with lipid membranes (termed lipid-binding loop [LBL]). Analogous loops exist in the HCs of BoNT/C, D, G, and a chimeric toxin DC. However, it has been challenging to detect and characterize binding of LBLs to lipid membranes. Here, using the nanodisc system and biolayer interferometry assays, we find that HC/DC, C, and G, but not HC/B and HC/D, are capable of binding to receptor-free lipids directly, with HC/DC having the highest level of binding. Mutagenesis studies demonstrate the critical role of consecutive aromatic residues at the tip of the LBL for binding of HC/DC to lipid membranes. Taking advantage of this insight, we then create a "gain-of-function" mutant HC/B by replacing two nonaromatic residues at the tip of its LBL with tryptophan. Cocrystallization studies confirm that these two tryptophan residues do not alter the structure of HC/B or the interactions with its receptors. Such a mutated HC/B gains the ability to bind receptor-free lipid membranes and shows enhanced binding to cultured neurons. Finally, full-length BoNT/B containing two tryptophan mutations in its LBL, together with two additional mutations (E1191M/S1199Y) that increase binding to human receptors, is produced and evaluated in mice in vivo using Digit Abduction Score assays. This mutant toxin shows enhanced efficacy in paralyzing local muscles at the injection site and lower systemic diffusion, thus extending both safety range and duration of paralysis compared with the control BoNT/B. These findings establish a mechanistic understanding of LBL-lipid interactions and create a modified BoNT/B with improved therapeutic efficacy.

N-linked Glycosylation of SV2 is Required for Binding and Uptake of Botulinum Neurotoxin A

Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Crystal Structure Of Botulinum Neurotoxin A2 In Complex With The Human Protein Receptor Sv2c Reveals Plasticity In Receptor Binding

Sv2 is the Protein Receptor for Botulinum Neurotoxin A

Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C

Crystal Structure of the Botulinum Neurotoxin Type G Binding Domain: Insight into Cell Surface Binding

Botulinum Neurotoxin D Uses Synaptic Vesicle Protein SV2 and Gangliosides As Receptors

Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B

Synaptotagmin Binding to Botulinum Neurotoxins

Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons.

Structural Basis for the Unique Ganglioside and Cell Membrane Recognition Mechanism of Botulinum Neurotoxin DC

None Detectable Retrograde Transport Of Chinese Botulinum Toxin Type A In Mice By Single Intramuscular Injection

Synaptotagmins I and II Mediate Entry of Botulinum Neurotoxin B into Cells

The C-Terminal Heavy-Chain Domain of Botulinum Neurotoxin A Is Not the Only Site That Binds Neurons, as the N-Terminal Heavy-Chain Domain Also Plays a Very Active Role in Toxin-Cell Binding and Interactions

Characterization of a Membrane Binding Loop Leads to Engineering Botulinum Neurotoxin B with Improved Therapeutic Efficacy.

Activity of Botulinum Neurotoxin X and Its Structure when Shielded by a Non-Toxic Non-Hemagglutinin Protein

Structure of Dual Receptor Binding to Botulinum Neurotoxin B

Identification and characterization of a novel botulinum neurotoxin

Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II.

Molecular Basis for Disruption of E-cadherin Adhesion by Botulinum Neurotoxin A Complex.